Welcome
Support Centre
09 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Medical Research Council Trial of Immediate versus Deferred Treatment for Intracerebral Brain Tumours Presenting With Epilepsy
ISRCTN ISRCTN46552426
ClinicalTrials.gov identifier
Public title Medical Research Council Trial of Immediate versus Deferred Treatment for Intracerebral Brain Tumours Presenting With Epilepsy
Scientific title
Acronym N/A
Serial number at source BR08
Study hypothesis Not provided at time of registration.
Lay summary
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial.
Countries of recruitment United Kingdom
Disease/condition/study domain Brain and Nervous System
Participants - inclusion criteria 1. Patients with a clinically definite history of epilepsy who have Computed Tomography (CT) and/or Magnetic Resonance (MR) imaging supporting a probable diagnosis of intracerebral tumour
2. Clinical picture, CT or MR imaging is unequivocal and allows exclusion of cerebral abscess or extra-axial tumour (meningioma)
3. No other medical condition likely to effect the feasibility of follow-up
4. No previous neurosurgery, radiotherapy or chemotherapy
5. No other previous or concurrent malignant disease, except non melanomatous carcinoma of the skin
6. Age >16
Participants - exclusion criteria Not provided at time of registration.
Anticipated start date 01/12/1988
Anticipated end date 10/12/1993
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration.
Interventions 1. Group A: Immediate treatment with clinicians choice of one or more of surgery, radiotherapy or chemotherapy, plus best medical treatment
2. Group B: Deferred treatment, with best medical treatment only until intervention becomes clinically necessary
Primary outcome measure(s) Not provided at time of registration.
Secondary outcome measure(s) Not provided at time of registration.
Sources of funding Medical Research Council (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 207 670 4723
  Fax +44 (0) 207 670 4818
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 19/08/2002
Last edited 24/11/2010
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central